iBio, Inc. is focused on development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases. To accelerate achievement of our objectives, we established a research & development relationship with a leading not-for-profit translational research institution, the Fraunhofer USA Center for Molecular Biotechnology (FhCMB). The success of this relationship has substantially reduced the risk of bringing important new medical products to market and has created a unique opportunity for investors.

We have achieved our initial goal of developing a platform technology for accelerated discovery and production of improved vaccines and therapeutics, and have applied our technology to create a pipeline of proprietary products, including vaccine and therapeutic candidates for seasonal and pandemic influenza, and other pathogens of public health significance.